Other substances

Calcifediol

The major metabolite of vitamin D3.

Phase of research

Potential treatment - clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

The major circulating metabolite of vitamin D3 (cholecalciferol). It is produced in the liver and is the best indicator of the body's vitamin D stores.

Calcifediol on DrugBank
Calcifediol on PubChem
Calcifediol on Wikipedia

Synonyms

Calcidiol; 25-hydroxyvitamin D3

CC(CCCC(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CCC3=C)O)C

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2 Preprint	human renal cortical epithelial cells			Apr/23/2020
Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study	patients		significantly reduced the need for ICU treatment of patients requiring hospitalization due to proven COVID-19	Aug/29/2020

AI-suggested references

Link	Publication date
Vitamin D receptor stimulation to reduce acute respiratory distress syndrome (ARDS) in patients with coronavirus SARS-CoV-2 infections	Jan/01/2021
Treatment With 25-Hydroxyvitamin D3 (Calcifediol) Is Associated With a Reduction in the Blood Neutrophil-to-Lymphocyte Ratio Marker of Disease Severity in Hospitalized Patients With COVID-19: A Pilot Multicenter, Randomized, Placebo-Controlled, Double-Bli	Oct/13/2021
Calcifediol Treatment and Hospital Mortality Due to COVID-19: A Cohort Study	May/21/2021
Calcifediol treatment and COVID-19-related outcomes	Aug/06/2021
A single-oral bolus of 100,000 IU of cholecalciferol at hospital admission did not improve outcomes in the COVID-19 disease: the COVID-VIT-D:a randomised multicentre international clinical trial	Dec/01/2020
Efficacy and Safety of Vitamin D Supplementation to Prevent COVID-19 in Frontline Healthcare Workers. A Randomized Clinical Trial	Feb/09/2022
"Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study".	Aug/29/2020

Clinical trials

ID	Title	Status	Phase	Start date	Completion date
NCT04366908	Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome	Recruiting	Phase 2	May/07/2020	Dec/30/2021
Alternative id - COVIDIOL Interventions - Drug: BAT + Calcifediol\|Drug: BAT Study type - Interventional Study results - No Results Available Locations - Hospital Universitario Reina Sofía, Cordoba, Spain Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 1008 Age - 18 Years to 90 Years (Adult, Older Adult) Outcome measures - Admission to Intensive Care Unit\|Death\|Time from onset of symptoms to discharge of patients in conventional hospitalization\|ICU - Time until admission\|ICU - Time mechanical ventilation is removed\|Evaluation of the inflammatory markers related with the disease\|Vitamin D metabolites\|Evolution in SatO2\|Evolution in the Sat O2/FiO2 ratio.\|Evolution in the degree of dyspnea\|Evolution of the improvement of radiological findings by simple radiology\|Incidence of adverse events\|Appearance of hemorrhagic or thrombotic phenomena
NCT04386850	Oral 25-hydroxyvitamin D3 and COVID-19	Recruiting	Phase 2\|Phase 3	Apr/14/2020	Mar/15/2021
Alternative id - IRCT2020-0401046909N2\|IRCT20200401046909N1 Interventions - Drug: Oral 25-Hydroxyvitamin D3 Study type - Interventional Study results - No Results Available Locations - Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\|Primary Purpose: Prevention Enrollment - 1500 Age - 18 Years to 75 Years (Adult, Older Adult) Outcome measures - COVID-19 (SARA-Cov-2) infection\|Severity of COVID-19 (SARA-Cov-2) infection\|Hospitalization\|Disease duration\|Death\|Oxygen support\|Type of oxygen support\|Symptoms of COVID-19\|Serum Levels of 25-hydroxyvitamin D3\|Serum levels of calcium\|Serum levels of phosphorus\|Serum levels of creatinine\|Serum levels of albumin\|Serum levels of the blood urea nitrogen (BUN)\|Serum levels of the parathyroid hormone (PTH)

Export (.csv)